Infectious side effects of baricitinib: A big data analysis based on VigiBase
| dc.authorid | 0000-0002-7919-1326 | |
| dc.authorid | 0000-0003-1555-4148 | |
| dc.authorid | 0000-0001-5784-726X | |
| dc.authorid | 0000-0001-8022-7325 | |
| dc.contributor.author | Mahroum, Naim | |
| dc.contributor.author | Özkan, Mehmet Fatih | |
| dc.contributor.author | Abalı, Tunahan | |
| dc.contributor.author | Yılmaz, Mesut | |
| dc.contributor.author | Bragazzi, Nicola Luigi | |
| dc.date.accessioned | 2023-01-06T08:26:40Z | |
| dc.date.available | 2023-01-06T08:26:40Z | |
| dc.date.issued | 2023 | |
| dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.description.abstract | Dear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus (SLE), and atopic dermatitis [1]. The first approval of baricitinib was from the European Medicines Agency (EMA) as a mon- otherapy or combination therapy with methotrexate for patients with RA unresponsive to disease-modifying anti-rheumatic drugs (DMARDs) | |
| dc.identifier.citation | Mahroum, N., Özkan, M. F., Abalı, T., Yılmaz, M. ve Bragazzi, N. L. (2023). Infectious side effects of baricitinib: A big data analysis based on VigiBase. Autoimmunity Reviews, 22(1). https://dx.doi.org/10.1016/j.autrev.2022.103215 | |
| dc.identifier.doi | 10.1016/j.autrev.2022.103215 | |
| dc.identifier.issn | 1568-9972 | |
| dc.identifier.issn | 1873-0183 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmid | 36270598 | |
| dc.identifier.scopus | 2-s2.0-85144637273 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://dx.doi.org/10.1016/j.autrev.2022.103215 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/10255 | |
| dc.identifier.volume | 22 | |
| dc.identifier.wos | 000911106400001 | en_US |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Mahroum, Naim | |
| dc.institutionauthor | Özkan, Mehmet Fatih | |
| dc.institutionauthor | Abalı, Tunahan | |
| dc.institutionauthor | Yılmaz, Mesut | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | Autoimmunity Reviews | en_US |
| dc.relation.publicationcategory | Diğer | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Baricitinib | |
| dc.subject | JAK Inhibitors | |
| dc.subject | Rheumatoid Arthritis | |
| dc.subject | Herpes Zoster | |
| dc.subject | Oral Herpes | |
| dc.title | Infectious side effects of baricitinib: A big data analysis based on VigiBase | |
| dc.type | Letter |
